A significant alert has been issued to individuals using Ozempic, Wegovy, and Mounjaro regarding a potential severe side effect that could arise from these medications. This warning comes at a time when approximately 1.6 million people in the UK have turned to these GLP-1 receptor agonists over the past year as a means to aid in weight loss.
The Medicines and Healthcare products Regulatory Agency (MHRA) has recently updated its guidance for both healthcare providers and patients, emphasizing the importance of recognizing symptoms associated with this rare but serious side effect. They have advised that anyone currently taking GLP-1 medications should seek immediate medical attention if they experience specific symptoms.
The key symptom to watch for is intense abdominal and back pain that persists. This discomfort may indicate acute pancreatitis, a condition characterized by inflammation and swelling of the pancreas, which is a vital organ located just behind the stomach.
For many individuals who develop this condition, recovery typically occurs within about a week, often without further complications. However, it's crucial to note that some patients may face more serious health issues as a result. The NHS has highlighted these concerns, reinforcing the need for vigilance among those using these medications.
In a press release, the MHRA stated that they had revised the product information intended for healthcare practitioners and patients, particularly those utilizing these drugs for weight management. Alison Cave, the Chief Safety Officer at MHRA, reiterated: "Ensuring patient safety remains our utmost priority. We continuously monitor the safety profiles and effectiveness of all licensed medications."
She continued to explain that while GLP-1 medications are generally deemed safe and effective for most patients, the overall risk of experiencing these severe side effects is relatively low. Nonetheless, it is vital for both patients and healthcare providers to remain aware of the symptoms related to this risk.
"If you or someone you know is on GLP-1s and notices symptoms such as severe, lasting stomach pain that may extend to the back, accompanied by nausea or vomiting, it’s essential to consult a healthcare professional immediately and report these incidents through our Yellow Card scheme," she added.
Wegovy and Mounjaro have been specifically authorized for prescription as weight loss treatments, whereas Ozempic is approved for managing diabetes as well as reducing the risk of heart attacks and strokes. In their statement, the MHRA clarified the intended uses of GLP-1 medications: "These drugs are prescribed for treating type 2 diabetes and, in certain cases, for weight management and lowering cardiovascular risks in patients with established heart disease and a body mass index (BMI) of 27 kg/m2 or higher."
Research conducted by University College London estimated that between early 2024 and early 2025, around 1.6 million adults across England, Wales, and Scotland used GLP-1 medications, including semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro), as part of their weight loss efforts.
While GLP-1s are widely recognized for their safety and efficacy, it’s important to remember that, like all medications, they come with certain risks. Patients who are prescribed GLP-1s should be well-informed about the signs of severe pancreatitis and are encouraged to seek urgent medical help if they encounter such symptoms.
According to the NHS, the most prevalent symptoms of acute pancreatitis include:
* Sudden onset of severe pain in the center of the abdomen
* Nausea or vomiting
* A high fever exceeding 38°C (100.4°F)
When should you seek medical assistance? The NHS strongly recommends seeing a GP right away if you experience sudden, intense abdominal pain. If a visit to your GP is not feasible, contacting NHS 111 for advice is also advised.
